114 related articles for article (PubMed ID: 37544503)
1. Urothelium-Specific Expression of Mutationally Activated Pik3ca Initiates Early Lesions of Noninvasive Bladder Cancer.
Shuman L; Pham J; Wildermuth T; Wu XR; Walter V; Warrick JI; DeGraff DJ
Am J Pathol; 2023 Dec; 193(12):2133-2143. PubMed ID: 37544503
[TBL] [Abstract][Full Text] [Related]
2. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation.
Adams JR; Xu K; Liu JC; Agamez NM; Loch AJ; Wong RG; Wang W; Wright KL; Lane TF; Zacksenhaus E; Egan SE
Cancer Res; 2011 Apr; 71(7):2706-17. PubMed ID: 21324922
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.
Ross RL; Askham JM; Knowles MA
Oncogene; 2013 Feb; 32(6):768-76. PubMed ID: 22430209
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
5. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.
Trejo CL; Green S; Marsh V; Collisson EA; Iezza G; Phillips WA; McMahon M
Cancer Res; 2013 Nov; 73(21):6448-61. PubMed ID: 24019382
[TBL] [Abstract][Full Text] [Related]
6. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
7. FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
Shi MJ; Fontugne J; Moreno-Vega A; Meng XY; Groeneveld C; Dufour F; Kamoun A; Viborg Lindskrog S; Cabel L; Krucker C; Rapinat A; Dunois-Larde C; Lepage ML; Chapeaublanc E; Levrel O; Dixon V; Lebret T; Almeida A; De Reynies A; Rochel N; Dyrskjøt L; Allory Y; Radvanyi F; Bernard-Pierrot I
Eur Urol; 2023 Jan; 83(1):70-81. PubMed ID: 36273937
[TBL] [Abstract][Full Text] [Related]
8. Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS.
Yee CH; Zheng Z; Shuman L; Yamashita H; Warrick JI; Wu XR; Raman JD; DeGraff DJ
Sci Rep; 2019 Jan; 9(1):270. PubMed ID: 30670749
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
[TBL] [Abstract][Full Text] [Related]
10. Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer.
Segovia C; Martínez-Fernández M; Dueñas M; Rubio C; López-Calderón FF; Costa C; Saiz-Ladera C; Fernández-Grajera M; Duarte J; Muñoz HG; de la Rosa F; Villacampa F; Castellano D; Paramio JM
Oncotarget; 2017 Feb; 8(6):10531-10542. PubMed ID: 28060766
[TBL] [Abstract][Full Text] [Related]
11. Trp53 Mutation in Keratin 5 (Krt5)-Expressing Basal Cells Facilitates the Development of Basal Squamous-Like Invasive Bladder Cancer in the Chemical Carcinogenesis of Mouse Bladder.
Masuda N; Murakami K; Kita Y; Hamada A; Kamada M; Teramoto Y; Sakatani T; Matsumoto K; Sano T; Saito R; Okuno Y; Ogawa O; Kobayashi T
Am J Pathol; 2020 Aug; 190(8):1752-1762. PubMed ID: 32339497
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
[TBL] [Abstract][Full Text] [Related]
13. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors.
Tikoo A; Roh V; Montgomery KG; Ivetac I; Waring P; Pelzer R; Hare L; Shackleton M; Humbert P; Phillips WA
PLoS One; 2012; 7(5):e36924. PubMed ID: 22666336
[TBL] [Abstract][Full Text] [Related]
14. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.
Xu H; Chen K; Shang R; Chen X; Zhang Y; Song X; Evert M; Zhong S; Li B; Calvisi DF; Chen X
Cell Death Dis; 2021 Oct; 12(10):920. PubMed ID: 34625531
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
Cheng H; Liu P; Ohlson C; Xu E; Symonds L; Isabella A; Muller WJ; Lin NU; Krop IE; Roberts TM; Winer EP; Arteaga CL; Zhao JJ
Oncogene; 2016 Jun; 35(23):2961-70. PubMed ID: 26640141
[TBL] [Abstract][Full Text] [Related]
17. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
[TBL] [Abstract][Full Text] [Related]
19. AKT1 and PIK3CA activating mutations in Moroccan bladder cancer patients´ biopsies and matched urine.
El Ahanidi H; El Azzouzi M; Arrouchi H; Alaoui CH; Tetou M; Bensaid M; Oukabli M; Ameur A; Al Bouzidi A; El Mzibri M; Attaleb M
Pan Afr Med J; 2022; 41():59. PubMed ID: 35317488
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN.
Chong X; Chen J; Zheng N; Zhou Z; Hai Y; Chen S; Zhang Y; Yu Q; Yu S; Chen Z; Bao W; Quan M; Chen ZS; Zhan Y; Gao Y
Mol Cancer; 2022 May; 21(1):118. PubMed ID: 35619132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]